Anti-tumor necrosis factor-alpha monoclonal antibody (anti-TNFα mAb) suppresses inflammation by inhibiting the activity of TNFα and is employed as a major therapeutic agent for immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) [1]. This evidence concerns the gene TNF and rheumatoid arthritis.